tirzepatide surpass trials Efficacy and safety of monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Tirzepatide is finally here –

Residual confounding and limitations in diagnostic coding may also influence results

However, much of the reported lean mass loss is actually from the liver and body water, not skeletal muscle

Clinical data shows women in trials experienced slightly higher weight loss (25.3%) compared to men (22.8%), suggesting particular effectiveness for female physiology

Tapering the dose rather than stopping cold turkey may help mitigate the shock to the system, though evidence on this is still emerging

TEAE = treatment-emergent adverse event

Pregnancy planning: Rybelsus must be discontinued at least 2 months before a planned pregnancy according to the SmPC